In moderate to severe UC or CD, immunomodulators and biologics are preferred for long-term maintenance due to superior inflammation control and favorable cardiovascular safety, with anti-TNF agents and newer biologics, including vedolizumab and ustekinumab, demonstrating no increased arrhythmia risk and potential indirect cardioprotection through systemic inflammation suppression [54]. This evidence concerns the gene TNF and Arrhythmia.